maprotiline ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1634 10262-69-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • maprotiline
  • maprotiline hydrochloride
  • maprotiline HCl
A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.
  • Molecular weight: 277.41
  • Formula: C20H23N
  • CLOGP: 4.52
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 12.03
  • ALOGS: -6.27
  • ROTB: 4

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O
0.10 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 3.13 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 3 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 11.59 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 68 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 45 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 14 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.11 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 51 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 1, 1980 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Polydipsia 60.41 33.02 14 1225 3550 63484233
Aspiration 49.21 33.02 15 1224 10836 63476947
Rhabdomyolysis 43.99 33.02 20 1219 43931 63443852
Mental disorder 39.87 33.02 16 1223 25903 63461880
Conjunctivitis 36.05 33.02 14 1225 20782 63467001
Embolic stroke 34.35 33.02 9 1230 3767 63484016

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 57.07 43.16 26 846 103105 79640411
Polydipsia 49.51 43.16 12 860 6593 79736923
Aspiration 44.45 43.16 14 858 20144 79723372

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AA21 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Non-selective monoamine reuptake inhibitors
MeSH PA D018663 Adrenergic Agents
MeSH PA D018759 Adrenergic Uptake Inhibitors
MeSH PA D000928 Antidepressive Agents
MeSH PA D018687 Antidepressive Agents, Second-Generation
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Depressive disorder indication 35489007
Mixed anxiety and depressive disorder indication 231504006
Neuralgia off-label use 16269008
Ocular hypertension contraindication 4210003 DOID:9282
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Sinus tachycardia contraindication 11092001
Bipolar disorder contraindication 13746004 DOID:3312
Myocardial infarction contraindication 22298006 DOID:5844
Hyperthyroidism contraindication 34486009 DOID:7998
Conduction disorder of the heart contraindication 44808001
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Seizure disorder contraindication 128613002
Cerebrovascular accident contraindication 230690007
Disease of liver contraindication 235856003 DOID:409
Retention of urine contraindication 267064002
Neutropenic disorder contraindication 303011007 DOID:1227
Surgical procedure contraindication 387713003
Angle-closure glaucoma contraindication 392291006 DOID:13550
Myocardial infarction in recovery phase contraindication 418044006
Central nervous system depression contraindication 418072004




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.91 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Kd 8.27 WOMBAT-PK CHEMBL
D(2) dopamine receptor GPCR Ki 6.18 WOMBAT-PK
Alpha-2A adrenergic receptor GPCR Ki 6.17 DRUG MATRIX
Cytochrome P450 3A4 Enzyme IC50 5.36 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 5.24 PDSP
5-hydroxytryptamine receptor 2A GPCR Ki 6.92 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 6.67 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 7.39 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 6.38 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 9.85 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 6.88 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.30 WOMBAT-PK
D(1B) dopamine receptor GPCR Ki 6.37 WOMBAT-PK
Histamine H1 receptor GPCR Ki 8.78 WOMBAT-PK
Histamine H2 receptor GPCR Ki 6.41 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.85 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 6.16 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 7 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 7.24 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 6.94 DRUG MATRIX
Aldehyde oxidase Enzyme IC50 5.85 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 6.36 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Kd 6 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 6.71 DRUG MATRIX
ATP-binding cassette sub-family G member 2 Transporter WOMBAT-PK
Voltage-dependent N-type calcium channel subunit alpha-1B Ion channel IC50 5 CHEMBL
D(1A) dopamine receptor GPCR Ki 6.31 WOMBAT-PK
Transient receptor potential cation channel subfamily M member 3 Ion channel BLOCKER IC50 5.80 IUPHAR
Alpha-1B adrenergic receptor GPCR Ki 7.05 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 6.25 CHEMBL
G protein-activated inward rectifier potassium channel 2 Ion channel BLOCKER IC50 4 IUPHAR

External reference:

IDSource
4019806 VUID
N0000147895 NUI
D00818 KEGG_DRUG
10347-81-6 SECONDARY_CAS_RN
4018785 VANDF
4019806 VANDF
C0024778 UMLSCUI
CHEBI:6690 CHEBI
CHEMBL21731 ChEMBL_ID
DB00934 DRUGBANK_ID
CHEMBL1237135 ChEMBL_ID
D008376 MESH_DESCRIPTOR_UI
4011 PUBCHEM_CID
2402 IUPHAR_LIGAND_ID
2763 INN_ID
2U1W68TROF UNII
203126 RXNORM
1567 MMSL
5023 MMSL
d00877 MMSL
001510 NDDF
004608 NDDF
10424009 SNOMEDCT_US
32823007 SNOMEDCT_US
387180003 SNOMEDCT_US

Pharmaceutical products:

None